Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Alzheimer Disease 10”

36 trials

Showing 20 of 36 results

Testing effectiveness (Phase 2)Study completedNCT00104273
What this trial is testing

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

Who this might be right for
DementiaAlzheimer's Disease
Teva Branded Pharmaceutical Products R&D, Inc. 376
Large-scale testing (Phase 3)Ended earlyNCT01739348
What this trial is testing

An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)

Who this might be right for
Alzheimer's Disease
Merck Sharp & Dohme LLC 2,211
Large-scale testing (Phase 3)Active Not RecruitingNCT06125951
What this trial is testing

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Who this might be right for
Dementia ModerateDementia, MildAlzheimer Disease
Actinogen Medical 247
Large-scale testing (Phase 3)Study completedNCT00506415
What this trial is testing

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Who this might be right for
Alzheimer Disease
Novartis Pharmaceuticals 1,584
Testing effectiveness (Phase 2)Study completedNCT00812565
What this trial is testing

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Octapharma 58
Post-approval studies (Phase 4)Study completedNCT00561392
What this trial is testing

Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Novartis 208
Post-approval studies (Phase 4)Study completedNCT00731224
What this trial is testing

Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.

Who this might be right for
Alzheimer's Disease
Novartis Pharmaceuticals 380
Post-approval studies (Phase 4)Study completedNCT00622713
What this trial is testing

A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)

Who this might be right for
Alzheimer's Disease
Novartis 228
Not applicableStudy completedNCT03212599
What this trial is testing

Disulfiram as a Modulator of Amyloid Precursor Protein-processing

Who this might be right for
Alcohol Addiction
Johannes Gutenberg University Mainz 17
Large-scale testing (Phase 3)Study completedNCT02550665
What this trial is testing

Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg

Who this might be right for
Alzheimer's Disease
Asan Medical Center 176
Early research (Phase 1)Study completedNCT01565330
What this trial is testing

Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Who this might be right for
Alzheimer Disease
Avid Radiopharmaceuticals 20
Large-scale testing (Phase 3)Study completedNCT00818662
What this trial is testing

Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Who this might be right for
Alzheimer´s Disease
Baxalta now part of Shire 390
Not applicableStudy completedNCT03534687
What this trial is testing

Exercise and the Receptor for Advanced Glycation End Products (RAGE)

Who this might be right for
Diabetes Mellitus, Type 2
University of Michigan 50
Large-scale testing (Phase 3)Study completedNCT00478205
What this trial is testing

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Eisai Inc. 1,467
Not applicableWithdrawnNCT04100889
What this trial is testing

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

Who this might be right for
Alzheimer DiseaseAlzheimer Disease 1Alzheimer Disease 2+20 more
ProgenaBiome
Not applicableStudy completedNCT05808530
What this trial is testing

Cognitive Stimulation Therapy

Who this might be right for
Alzheimer Disease 10DementiaApathy+2 more
Hasan Kalyoncu University 56
Large-scale testing (Phase 3)Study completedNCT01399125
What this trial is testing

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Novartis Pharmaceuticals 501
Post-approval studies (Phase 4)Study completedNCT01529619
What this trial is testing

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Who this might be right for
Alzheimer's Disease
Novartis Pharmaceuticals 52
Post-approval studies (Phase 4)Study completedNCT00234637
What this trial is testing

Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment

Who this might be right for
Alzheimer's Disease
Novartis 204
Post-approval studies (Phase 4)Study completedNCT02703636
What this trial is testing

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

Who this might be right for
Mild to Moderate Alzheimer's Disease
Novartis Pharmaceuticals 118
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation